PURPOSE: Quinacrine is a relatively non-toxic drug, once given almost exclusively for malaria. However, recent studies show that quinacrine can suppress nuclear factor-κB (NF-κB), and activate p53 signaling. We investigated the anti-cancer effect of quinacrine, using a novel mouse model of isolated limb perfusion (ILP) for extremity melanoma. METHOD: Female C57BL/6 mice (22-25 g) were injected with B16 melanoma cells (1 × 10(5)) subcutaneously in the distal thigh. After 7 days of tumor establishment, mice were perfused with either PBS, melphalan (90 µg), or quinacrine (3.5 and 4.5 mg) through the superficial femoral artery for 30 min at either 37 or 42 °C in a non-oxygenated circuit. We analyzed morbidity, toxicity, tumor apoptosis, and responses. RESULTS: Melanoma cell death following in vitro exposure to quinacrine was dose and time dependent. A significant decrease in mean tumor volume was observed after perfusion with low-dose and high-dose quinacrine (both P = 0.002) at 37 °C as well as after perfusion with low-dose quinacrine (P = 0.0008) at 42 °C. CONCLUSION: Quinacrine has demonstrable efficacy against melanoma cells in vitro and in a clinically relevant model of ILP. Further studies to evaluate the optimal conditions for quinacrine usage are warranted.
PURPOSE:Quinacrine is a relatively non-toxic drug, once given almost exclusively for malaria. However, recent studies show that quinacrine can suppress nuclear factor-κB (NF-κB), and activate p53 signaling. We investigated the anti-cancer effect of quinacrine, using a novel mouse model of isolated limb perfusion (ILP) for extremity melanoma. METHOD: Female C57BL/6 mice (22-25 g) were injected with B16 melanoma cells (1 × 10(5)) subcutaneously in the distal thigh. After 7 days of tumor establishment, mice were perfused with either PBS, melphalan (90 µg), or quinacrine (3.5 and 4.5 mg) through the superficial femoral artery for 30 min at either 37 or 42 °C in a non-oxygenated circuit. We analyzed morbidity, toxicity, tumor apoptosis, and responses. RESULTS:Melanoma cell death following in vitro exposure to quinacrine was dose and time dependent. A significant decrease in mean tumor volume was observed after perfusion with low-dose and high-dose quinacrine (both P = 0.002) at 37 °C as well as after perfusion with low-dose quinacrine (P = 0.0008) at 42 °C. CONCLUSION:Quinacrine has demonstrable efficacy against melanoma cells in vitro and in a clinically relevant model of ILP. Further studies to evaluate the optimal conditions for quinacrine usage are warranted.
Authors: J M Klaase; B B Kroon; A M Eggermont; A N van Geel; H Schraffordt Koops; J Oldhoff; D Liénard; F J Lejeune; R Berkel; H R Franklin Journal: Eur J Cancer Date: 1995 Impact factor: 9.162
Authors: F Di Filippo; M Anzà; C R Rossi; F Cavaliere; C Botti; M Lise; R Garinei; D Giannarelli; S Vasselli; G Zupi; R Cavaliere Journal: Semin Surg Oncol Date: 1998 Apr-May
Authors: Eleni Linos; Susan M Swetter; Myles G Cockburn; Graham A Colditz; Christina A Clarke Journal: J Invest Dermatol Date: 2009-01-08 Impact factor: 8.551
Authors: Elizabeth G Grubbs; Tomio Ueno; Omar Abdel-Wahab; Tsung-Yen Cheng; Scott K Pruitt; O Michael Colvin; Henry S Friedman; Douglas S Tyler Journal: Surgery Date: 2004-08 Impact factor: 3.982
Authors: Minhyung Kim; Tara A Barone; Natalia Fedtsova; Anatoli Gleiberman; Chandler D Wilfong; Julie A Alosi; Robert J Plunkett; Andrei Gudkov; Joseph J Skitzki Journal: J Neurooncol Date: 2015-09-16 Impact factor: 4.130